Long term Evaluation of Dabigatran 150 versus 110 mg BID in Patients with Non-Valvular Atrial Fibrillation
Authors
Ezekowitz MD, DPhil, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener H-C, Wallentin L, Yusuf S, Connolly SJ
Journal
Europace
Publication Date
2016
Impact Factor
3.670
Abstract
Additional IDs
Long term Evaluation of Dabigatran 150 versus 110 mg BID in Patients with Non-Valvular Atrial Fibrillation - Publication by Dr. Andreas Clemens | Dr. Andreas Clemens